Stock 3KY HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hansoh Pharmaceutical Group Company Limited Börse Stuttgart

Equities

3KY

KYG549581067

Pharmaceuticals

Market Closed - Börse Stuttgart
Other stock markets
 04:30:58 2024-06-28 EDT 		After market 15:24:39
1.93 EUR -0.52% Intraday chart for Hansoh Pharmaceutical Group Company Limited 1.945 +0.78%
06-14 Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds MT
04-30 Hansoh Pharmaceutical’s 2023 Profit Up 27% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 133,984 187,313 91,686 77,600 84,854 89,962 - -
Enterprise Value (EV) 1 122,171 173,688 76,984 59,985 64,732 68,727 66,101 62,269
P/E ratio 51.7 x 71.9 x 35.2 x 29.8 x 26 x 23.5 x 23.6 x 20.5 x
Yield - 0.21% 0.47% 0.76% 1.49% 1.01% 1.05% 1.11%
Capitalization / Revenue 15.4 x 21.6 x 9.23 x 8.27 x 8.4 x 7.6 x 7.21 x 6.44 x
EV / Revenue 14.1 x 20 x 7.75 x 6.39 x 6.41 x 5.81 x 5.3 x 4.45 x
EV / EBITDA 40.9 x 57.7 x 24.2 x 19.9 x 20.9 x 16 x 15.2 x 12.4 x
EV / FCF 44.5 x 180 x 36.6 x 24.3 x 23.5 x 19.4 x 16.9 x 14.9 x
FCF Yield 2.25% 0.55% 2.73% 4.12% 4.25% 5.15% 5.92% 6.73%
Price to Book 10.3 x 10.5 x 4.58 x 3.43 x 3.29 x 3.15 x 2.86 x 2.56 x
Nbr of stocks (in thousands) 5,788,611 5,918,991 5,922,350 5,920,764 5,923,735 5,923,035 - -
Reference price 2 23.15 31.65 15.48 13.11 14.32 15.19 15.19 15.19
Announcement Date 20-03-30 21-03-30 22-03-29 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 8,683 8,690 9,935 9,382 10,104 11,830 12,478 13,978
EBITDA 1 2,990 3,008 3,175 3,019 3,101 4,299 4,343 5,007
EBIT 1 2,788 2,775 2,897 2,674 2,735 3,866 3,906 4,484
Operating Margin 32.11% 31.93% 29.16% 28.5% 27.07% 32.68% 31.3% 32.08%
Earnings before Tax (EBT) 1 3,001 3,098 3,300 2,948 3,766 4,356 4,482 5,155
Net income 1 2,557 2,569 2,713 2,584 3,278 3,773 3,790 4,416
Net margin 29.45% 29.56% 27.31% 27.54% 32.44% 31.9% 30.37% 31.59%
EPS 2 0.4481 0.4400 0.4400 0.4400 0.5500 0.6470 0.6435 0.7404
Free Cash Flow 1 2,748 962.8 2,102 2,470 2,754 3,539 3,912 4,189
FCF margin 31.65% 11.08% 21.16% 26.33% 27.26% 29.91% 31.35% 29.97%
FCF Conversion (EBITDA) 91.91% 32.01% 66.2% 81.83% 88.8% 82.32% 90.08% 83.66%
FCF Conversion (Net income) 107.49% 37.48% 77.48% 95.62% 84.03% 93.78% 103.22% 94.85%
Dividend per Share 2 - 0.0651 0.0732 0.1000 0.2129 0.1537 0.1594 0.1682
Announcement Date 20-03-30 21-03-30 22-03-29 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 4,083 3,980 4,711 4,402 5,534 4,434 4,948 4,511 5,593 6,186 5,718 5,485 6,682
EBITDA - - - - - - - - - - - - -
EBIT 1 - - - 1,337 1,560 1,322 1,353 1,047 1,688 2,074 1,118 1,520 1,049
Operating Margin - - - 30.38% 28.19% 29.8% 27.34% 23.2% 30.19% 33.54% 19.55% 27.72% 15.7%
Earnings before Tax (EBT) - - - - - - - - 2,266 - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS - - - - - - 0.2200 - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 20-03-30 20-09-17 21-03-30 21-08-26 22-03-29 22-08-26 23-03-27 23-09-28 24-03-26 - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 11,812 13,625 14,702 17,615 20,122 21,235 23,861 27,693
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,748 963 2,102 2,470 2,754 3,539 3,912 4,189
ROE (net income / shareholders' equity) 33% 16.6% 14.3% 12.1% 13.5% 13.5% 12.4% 12.6%
ROA (Net income/ Total Assets) 18.3% 12.7% 11.3% 9.04% 10.4% 11% 10.7% 11.1%
Assets 1 14,002 20,184 23,976 28,581 31,521 34,392 35,533 39,859
Book Value Per Share 2 2.250 3.020 3.380 3.820 4.350 4.820 5.320 5.930
Cash Flow per Share 2 0.6100 0.4100 0.4300 0.4600 0.5200 0.6600 0.6500 0.8500
Capex 1 581 1,428 460 271 363 478 463 481
Capex / Sales 6.7% 16.43% 4.63% 2.89% 3.59% 4.04% 3.71% 3.44%
Announcement Date 20-03-30 21-03-30 22-03-29 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
15.19 CNY
Average target price
18.11 CNY
Spread / Average Target
+19.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 819B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.26% 329B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 225B
NOVARTIS AG Stock Novartis AG
+13.31% 217B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.80% 158B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. 3KY Stock
  5. Financials Hansoh Pharmaceutical Group Company Limited